Percutaneous Aortic Valve – the Canadian Experience: Present and Future Perspectives (pp. 275-292)
Authors: (Gilbert H.L. Tang, Mark Osten, Eric Horlick, Christopher M. Feindel)
Abstract: Canada has been at the forefront of transcatheter aortic valve intervention (TAVI) since its initial inception. Both Edwards‘ balloon expandable valve and Medtronic‘s self expanding Corevalve have been used in different Canadian centers. Experience in transfemoral and transapical approaches, as well as valve-in-valve procedures have been reported. Combined multi-center experience with the Edwards valve demonstrates favorable short- and mid-term outcomes similar to those reported in Europe and the Placement of AoRTic TraNscathetER Valve B (PARTNER B) trial. In a publicly funded health care system, access to transcatheter valves has been restricted to the Special Access Program and requires case by case approval by Health Canada. Funding of most Canadian TAVI programs is currently through non-governmental sources and remains a significant challenge. Nonetheless, this emerging therapy will remain an important option for high risk inoperable patients and Canada will continue to play a leading role in the innovation and adoption of transcatheter valve technologies.